论文部分内容阅读
目的观察吡格列酮联合替米沙坦对早期糖尿病肾病(Ⅲ期)的临床疗效。方法 38例患者随机分成3组,随访时间均为3月;观察3组治疗前后空腹血糖(FBG)、餐后2h血糖(2hBG)、糖化血红蛋白(HbA1c)、尿白蛋白排泄率(UAER)、肾功能(BUN、SCr)、肝功(ALT)和血钾(K+)等变化。结果 3组治疗后UAER均有显著下降(P<0.05),联合用药组治疗后下降更为明显(P<0.01)。结论吡格列酮和替米沙坦在糖尿病肾病中均能减少尿白蛋白,且联合用药疗效优于单一用药。
Objective To observe the clinical effect of pioglitazone and telmisartan on early diabetic nephropathy (Ⅲ). Methods 38 patients were randomly divided into 3 groups and the follow-up time was March. The fasting blood glucose (FBG), postprandial blood glucose (2hBG), HbA1c, urinary albumin excretion rate (UAER) Renal function (BUN, SCr), liver function (ALT) and serum potassium (K +) and other changes. Results The UAER of three groups decreased significantly after treatment (P <0.05), but decreased more significantly in the combination group after treatment (P <0.01). Conclusion Both pioglitazone and telmisartan can reduce urinary albumin in diabetic nephropathy, and the combination therapy is better than single therapy.